CN107922401B - 用于治疗心血管病症的4-羟基-3-(杂芳基)吡啶-2-酮apj激动剂 - Google Patents
用于治疗心血管病症的4-羟基-3-(杂芳基)吡啶-2-酮apj激动剂 Download PDFInfo
- Publication number
- CN107922401B CN107922401B CN201680045336.7A CN201680045336A CN107922401B CN 107922401 B CN107922401 B CN 107922401B CN 201680045336 A CN201680045336 A CN 201680045336A CN 107922401 B CN107922401 B CN 107922401B
- Authority
- CN
- China
- Prior art keywords
- oxadiazol
- dimethoxyphenyl
- butyl
- methyl
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170215P | 2015-06-03 | 2015-06-03 | |
| US62/170,215 | 2015-06-03 | ||
| PCT/US2016/035482 WO2016196771A1 (en) | 2015-06-03 | 2016-06-02 | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107922401A CN107922401A (zh) | 2018-04-17 |
| CN107922401B true CN107922401B (zh) | 2021-04-16 |
Family
ID=56131647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680045336.7A Active CN107922401B (zh) | 2015-06-03 | 2016-06-02 | 用于治疗心血管病症的4-羟基-3-(杂芳基)吡啶-2-酮apj激动剂 |
Country Status (36)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050317T2 (hu) | 2015-05-20 | 2020-11-30 | Amgen Inc | APJ receptor triazol agonistái |
| LT3303330T (lt) * | 2015-06-03 | 2019-08-12 | Bristol-Myers Squibb Company | 4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui |
| CA3001974A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as apj agonists |
| JP6817305B2 (ja) | 2015-12-04 | 2021-01-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アペリン受容体アゴニストおよびその使用方法 |
| EP3390400B1 (en) * | 2015-12-16 | 2021-01-20 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
| EA037162B1 (ru) * | 2016-03-24 | 2021-02-12 | Бристол-Маерс Сквибб Компани | 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| ES2844184T3 (es) * | 2016-06-14 | 2021-07-21 | Bristol Myers Squibb Co | 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ |
| CN109311821B (zh) | 2016-06-14 | 2022-10-14 | 百时美施贵宝公司 | 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮 |
| KR102521956B1 (ko) * | 2016-10-14 | 2023-04-14 | 브리스톨-마이어스 스큅 컴퍼니 | 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제 |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| EP3541802B1 (en) | 2016-11-16 | 2025-01-01 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| CN109704980B (zh) * | 2019-02-16 | 2022-05-13 | 安徽大学 | 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法 |
| CN109704981B (zh) * | 2019-02-16 | 2022-01-28 | 安徽诺全药业有限公司 | 取代合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法 |
| CN109734616B (zh) * | 2019-02-16 | 2022-05-13 | 安徽诺全药业有限公司 | 两步法合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法 |
| TW202438513A (zh) | 2023-01-03 | 2024-10-01 | 美商百愛及生物醫藥公司 | 用於治療與體重增加相關之疾病或病症之愛帕琳(apelin)受體促效劑及glp-1受體促效劑之組合療法 |
| WO2025213190A1 (en) | 2024-04-05 | 2025-10-09 | BioAge Labs, Inc. | Methods of treating a disease or condition associated with weight gain |
| WO2025251084A1 (en) | 2024-05-31 | 2025-12-04 | BioAge Labs, Inc. | Methods of treating a disease or condition associated with weight gain |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1001159A (en) | 1910-07-25 | 1911-08-22 | Elizabeth Nielsen | Skirt-gage. |
| GB1472257A (en) | 1973-09-10 | 1977-05-04 | Christiaens Sa A | Derivative of 4-hydroxy-5-azacoumarin |
| US4866182A (en) | 1988-02-18 | 1989-09-12 | Merrell Dow Pharmaceuticals Inc. | Cardiotonic alkanoyl and aroyl oxazolones |
| US5338740A (en) | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
| JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
| CA2438991C (en) | 2001-02-21 | 2010-08-17 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| KR100564466B1 (ko) | 2001-03-28 | 2006-03-29 | 화이자 인코포레이티드 | Ｆｓａｄ에 대한 ｎｅｐ 억제제로서의ｎ-펜프로필사이클로펜틸-치환된 글루타르아미드 유도체 |
| US7399759B2 (en) | 2001-09-03 | 2008-07-15 | Takeda Pharmaceutical Company Limited | 1, 3-benzothiazinone derivatives and use thereof |
| JP2005170790A (ja) | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | Ｎ−アルキルスルフォニル置換アミド誘導体 |
| JP2005162612A (ja) | 2002-01-09 | 2005-06-23 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| SI1490064T1 (sl) * | 2002-02-14 | 2010-01-29 | Pharmacia Corp | Substituirani piridinoni kot modulatorji p38 MAP kinaze |
| US20040147561A1 (en) * | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
| US20090048301A1 (en) | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| US20060004001A1 (en) | 2004-02-27 | 2006-01-05 | Merz Pharma Gmbh & Co., Kgaa | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| ATE454372T1 (de) | 2004-04-01 | 2010-01-15 | Lilly Co Eli | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen |
| CA2565437A1 (en) | 2004-06-18 | 2006-01-05 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| EP1786790B1 (en) | 2004-07-26 | 2009-06-03 | Eli Lilly And Company | Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
| EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| US20090215777A1 (en) | 2005-05-19 | 2009-08-27 | Astex Therapeutics Ltd. | Pyrimidine Derivatives As HSP90 Inhibitors |
| WO2007023242A1 (en) | 2005-08-24 | 2007-03-01 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
| HUE028504T2 (en) | 2006-01-23 | 2016-12-28 | Amgen Inc | Aurora kinase modulators and method for their application |
| JP2007314516A (ja) | 2006-04-25 | 2007-12-06 | Daiichi Sankyo Co Ltd | ２以上の置換基を有するベンゼン化合物を含有する医薬 |
| MX2009001279A (es) | 2006-08-03 | 2009-02-11 | Tufts College | Analogos de niacina no eritematosos, y metodos para utilizar los mismos. |
| WO2008019090A2 (en) | 2006-08-04 | 2008-02-14 | Praecis Pharmaceuticals Incorporated | Agonists of the sphingosine-1-phosphate receptor |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| US20100035860A1 (en) | 2006-12-01 | 2010-02-11 | Jey Raju Jeyaseelan | Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy |
| WO2008116911A1 (en) | 2007-03-28 | 2008-10-02 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
| US20090136473A1 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
| US20110034378A1 (en) | 2008-01-25 | 2011-02-10 | Chaitanya Dutt | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. |
| JP5637982B2 (ja) | 2008-04-09 | 2014-12-10 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 脂肪酸アミド加水分解酵素の阻害剤 |
| JP2011523997A (ja) | 2008-05-30 | 2011-08-25 | フォスター ホイーラー エナージア オサケ ユキチュア | 酸素燃焼によって動力を発生させるための方法及び装置 |
| US8124649B2 (en) | 2008-06-30 | 2012-02-28 | Cylene Pharmaceuticals, Inc. | Oxindole compounds |
| US8501804B2 (en) | 2008-10-27 | 2013-08-06 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
| AU2009311640B2 (en) * | 2008-11-04 | 2013-09-26 | Anchor Therapeutics, Inc. | APJ receptor compounds |
| BR112012006628A2 (pt) | 2009-09-24 | 2016-05-03 | Hoffmann La Roche | compostos antivírus heterocíclos |
| JP2013505913A (ja) | 2009-09-24 | 2013-02-21 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｒａｃ調節剤としてのインドール誘導体 |
| WO2011062955A2 (en) | 2009-11-18 | 2011-05-26 | University Of Massachusetts | Compounds for modulating tlr2 |
| MX2012006913A (es) | 2009-12-18 | 2012-08-23 | Activesite Pharmaceuticals Inc | Profarmacos de inhibidores de calicreina plasmatica. |
| CN102241621A (zh) | 2010-05-11 | 2011-11-16 | 江苏恒瑞医药股份有限公司 | 5,5-双取代-2-亚氨基吡咯烷类衍生物、其制备方法及其在医药上的应用 |
| EP2578573A4 (en) | 2010-05-24 | 2014-08-06 | Toa Eiyo Ltd | CONDENSATE IMIDAZOLE DERIVATIVE |
| JP5869579B2 (ja) * | 2010-09-24 | 2016-02-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用 |
| WO2012074022A1 (ja) | 2010-12-01 | 2012-06-07 | 旭硝子株式会社 | イリジウムカチオン錯体および発光組成物 |
| WO2012117097A1 (en) | 2011-03-03 | 2012-09-07 | Universität des Saarlandes | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
| EP2697196A1 (en) | 2011-04-13 | 2014-02-19 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| JP6130827B2 (ja) | 2011-05-17 | 2017-05-17 | 塩野義製薬株式会社 | ヘテロ環化合物 |
| EP2794601B1 (en) | 2011-12-23 | 2019-02-20 | Basf Se | Isothiazoline compounds for combating invertebrate pests |
| IN2014MN02126A (enExample) * | 2012-05-02 | 2015-09-11 | Lupin Ltd | |
| BR112014027133A2 (pt) | 2012-05-09 | 2017-06-27 | Basf Se | compostos, composição agrícola ou veterinária, método para o controle das pragas de invertebrados, material de propagação dos vegetais e método para o tratamento ou proteção de um animal. |
| US9359284B2 (en) | 2012-06-08 | 2016-06-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Benzathine analogs |
| EP2866803A1 (en) | 2012-07-02 | 2015-05-06 | Max-Delbrück-Centrum für Molekulare Medizin Berlin-Buch | Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy |
| CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| EP2888256A4 (en) | 2012-08-24 | 2016-02-17 | Univ Texas | HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES |
| WO2014044738A1 (en) * | 2012-09-21 | 2014-03-27 | Sanofi | Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators |
| WO2014062938A1 (en) | 2012-10-19 | 2014-04-24 | Bristol-Myers Squibb Company | Rory modulators |
| CA2905509A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
| EP3027625B1 (en) | 2013-07-31 | 2018-05-30 | Merck Sharp & Dohme Corp. | Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure |
| JP6199197B2 (ja) | 2014-02-07 | 2017-09-20 | 花王株式会社 | ポリオキシアルキレンアルキルエーテルカルボン酸塩の製造方法 |
| JP2017071553A (ja) | 2014-02-25 | 2017-04-13 | 味の素株式会社 | ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物 |
| KR20160127138A (ko) | 2014-03-20 | 2016-11-02 | 바이엘 파마 악티엔게젤샤프트 | 신규 화합물 |
| WO2015191630A1 (en) | 2014-06-10 | 2015-12-17 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
| HUE050317T2 (hu) | 2015-05-20 | 2020-11-30 | Amgen Inc | APJ receptor triazol agonistái |
| LT3303330T (lt) * | 2015-06-03 | 2019-08-12 | Bristol-Myers Squibb Company | 4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui |
| KR101711744B1 (ko) | 2015-07-16 | 2017-03-02 | 경희대학교 산학협력단 | 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층 |
| CA3001974A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as apj agonists |
| WO2017091513A1 (en) | 2015-11-24 | 2017-06-01 | Daiichi Sankyo Company, Limited | Novel azole derivatives as apelin receptor agonist |
| JP6817305B2 (ja) | 2015-12-04 | 2021-01-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アペリン受容体アゴニストおよびその使用方法 |
| PE20190258A1 (es) | 2015-12-09 | 2019-02-25 | Res Triangle Inst | Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos |
| EP3390400B1 (en) | 2015-12-16 | 2021-01-20 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
| EA037162B1 (ru) | 2016-03-24 | 2021-02-12 | Бристол-Маерс Сквибб Компани | 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj |
| ES2844184T3 (es) | 2016-06-14 | 2021-07-21 | Bristol Myers Squibb Co | 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ |
| CN109311821B (zh) | 2016-06-14 | 2022-10-14 | 百时美施贵宝公司 | 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮 |
| KR102521956B1 (ko) | 2016-10-14 | 2023-04-14 | 브리스톨-마이어스 스큅 컴퍼니 | 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제 |
-
2016
- 2016-06-02 LT LTEP16729454.5T patent/LT3303330T/lt unknown
- 2016-06-02 RS RSP20190961 patent/RS59220B1/sr unknown
- 2016-06-02 WO PCT/US2016/035482 patent/WO2016196771A1/en not_active Ceased
- 2016-06-02 PH PH1/2017/502158A patent/PH12017502158B1/en unknown
- 2016-06-02 HK HK18107278.8A patent/HK1247915B/en unknown
- 2016-06-02 MX MX2017014956A patent/MX378998B/es unknown
- 2016-06-02 PE PE2017002482A patent/PE20180506A1/es unknown
- 2016-06-02 KR KR1020177037657A patent/KR102066336B1/ko active Active
- 2016-06-02 MA MA41562A patent/MA41562B1/fr unknown
- 2016-06-02 EA EA201792548A patent/EA034912B1/ru not_active IP Right Cessation
- 2016-06-02 EP EP19168724.3A patent/EP3530660A1/en not_active Withdrawn
- 2016-06-02 HU HUE16729454A patent/HUE045546T2/hu unknown
- 2016-06-02 SM SM20190427T patent/SMT201900427T1/it unknown
- 2016-06-02 NZ NZ73856316A patent/NZ738563A/en unknown
- 2016-06-02 CN CN201680045336.7A patent/CN107922401B/zh active Active
- 2016-06-02 TW TW105117468A patent/TWI672299B/zh active
- 2016-06-02 ME MEP-2019-211A patent/ME03474B/me unknown
- 2016-06-02 PT PT16729454T patent/PT3303330T/pt unknown
- 2016-06-02 JP JP2017562603A patent/JP6483288B2/ja active Active
- 2016-06-02 UY UY0001036705A patent/UY36705A/es unknown
- 2016-06-02 CA CA2988147A patent/CA2988147C/en active Active
- 2016-06-02 SI SI201630316T patent/SI3303330T1/sl unknown
- 2016-06-02 US US15/171,276 patent/US10011594B2/en active Active
- 2016-06-02 EP EP16729454.5A patent/EP3303330B1/en active Active
- 2016-06-02 DK DK16729454.5T patent/DK3303330T3/da active
- 2016-06-02 PL PL16729454T patent/PL3303330T3/pl unknown
- 2016-06-02 AR ARP160101639A patent/AR104884A1/es unknown
- 2016-06-02 ES ES16729454T patent/ES2739526T3/es active Active
- 2016-06-02 AU AU2016270903A patent/AU2016270903B2/en active Active
- 2016-06-02 MY MYPI2017704612A patent/MY189453A/en unknown
- 2016-06-02 TN TNP/2017/000503A patent/TN2017000503A1/en unknown
- 2016-06-02 HR HRP20191327 patent/HRP20191327T1/hr unknown
-
2017
- 2017-11-27 IL IL255951A patent/IL255951B/en active IP Right Grant
- 2017-11-30 CL CL2017003055A patent/CL2017003055A1/es unknown
- 2017-12-01 ZA ZA2017/08191A patent/ZA201708191B/en unknown
- 2017-12-21 CO CONC2017/0013229A patent/CO2017013229A2/es unknown
-
2018
- 2018-05-29 US US15/990,855 patent/US10336739B2/en active Active
-
2019
- 2019-02-13 JP JP2019023478A patent/JP2019094345A/ja active Pending
- 2019-05-14 US US16/411,221 patent/US20190263791A1/en not_active Abandoned
- 2019-07-29 CY CY20191100803T patent/CY1121938T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107922401B (zh) | 用于治疗心血管病症的4-羟基-3-(杂芳基)吡啶-2-酮apj激动剂 | |
| CN108368087B (zh) | 作为apj激动剂的2，4-二羟基-烟酰胺 | |
| CN109195963B (zh) | 作为apj激动剂的6-羟基-4-氧代-1，4-二氢嘧啶-5-甲酰胺 | |
| CN108473466B (zh) | 爱帕琳肽受体激动剂及使用方法 | |
| CN108602813B (zh) | 作为apj受体激动剂的杂芳基羟基嘧啶酮 | |
| KR102384668B1 (ko) | Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온 | |
| CN109641843B (zh) | 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮 | |
| HK1247915A1 (en) | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders | |
| CN110072850A (zh) | 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂 | |
| BR112017024846B1 (pt) | Agonistas de apj de 4-hidróxi-3-(heteroaril)piridina-2- ona, seu uso e composição farmacêutica que os compreende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |